Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Vs. EU: Is Cell And Gene Therapy Reimbursement Easier Stateside?

Some Gene Therapy Manufacturers Have Opted Out Of Europe

Executive Summary

A bluebird executive spoke during ARM’s Cell and Gene Meeting On The Mesa about why the firm pulled Zynteglo out of the EU, but while progress has been made in the US, long-term challenges remain.

You may also be interested in...



Tough Times In Europe For Gene Therapy Companies

bluebird bio's decision to wind down commercial initiatives for its gene therapy business in Europe is a blow for the sector in the region as a whole. 

Lessons From Bluebird Bio: How To Launch Advanced Therapies in Germany

Outcomes-based deals are important for launching cell and gene therapies in Germany, but bluebird bio’s painful experience with Zynteglo shows the importance of the taking the right approach to ensure market success.

Novartis Steers Zolgensma Towards Commercial Success In Europe

The head of Novartis Gene Therapies in Europe tells Scrip that innovative payment models and involving all stakeholders have helped payers see beyond a simple price tag and see the benefits of a one-time gene therapy for spinal muscular atrophy.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145234

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel